MTSL Issue 918
MTSL Issue 918 (dated 01/09/20) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #biomarin #XON #intrexon #INCY #incyte #MYOV #myovant #NKTR #nektar #PCRX #pacira #SGMO #sangamo
MTSL Issue 909
MTSL Issue 909 (dated 8/22/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #incyte #XON #intrexon #MYOV #myovant
MTSL Issue 905
MTSL Issue 905 (dated 6/27/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #esperion #INCY #incyte #XON #intrexon #SGMO #sangamo #ZYNE #zynerba
MTSL Issue 899
MTSL Issue 899 (dated 4/04/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #XON #NKTR #SGMO
MTSL Issue 898
MTSL Issue 898 (dated 3/14/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #XON #IONS #PCRX #ZIOP
MTSL Issue 887
MTSL Issue 887 (dated 10/04/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #MDCO #XON #NKTR
MTSL Issue 878
MTSL Issue 878 (dated 05/24/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #ESPR #XON #SGMO #ZIOP
MTSL Issue 874
MTSL Issue 874 (dated 03/29/18) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #FPRX #IONS #XON #MDGL
MTSL Issue 865
MTSL Issue 865 (dated 11/23/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #FPRX #XON #NKTR #PCRX #SGMO #ZIOP
MTSL Issue 863
MTSL Issue 863 (dated 10/26/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #XON #MDGL #MDCO
MTSL Issue 858
MTSL Issue 858 (dated 8/17/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ANTH #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MDGL #NKTR #PCRX #SGMO #XON #ZIOP
MTSL Issue 856
MTSL Issue 856 (dated 7/13/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #IONS #INCY #XON #NKTR #SGMO
Intrexon: Biotech, Biofuels & Fish Farming
Intrexon (XON) has had a very busy few weeks as the company has delivered a slew of positive news, explains John McCamant, editor of The Medical Technology Stock Letter.
MTSL Issue 854
MTSL Issue 854 (dated 6/15/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #INCY #XON #NKTR #FPRX #ZIOP
MTSL Issue 852
MTSL Issue 852 (dated 5/18/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #XON #IONS #NKTR #NVAX #SGMO #ZIOP
MTSL Issue 848
MTSL Issue 848 (dated 3/16/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ANTH #ESPR #IONS #XON #MDCO #OGXI #PCRX
MTSL Issue 847
MTSL Issue 847 (dated 3/02/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #FPRX #INCY #XON #IONS #MDCO #NKTR #PCRX #SGMO
MTSL Issue 845
MTSL Issue 845 (dated 2/02/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #XON #MDCO #NVAX #PCRX
MTSL Issue 839
MTSL Issue 839 (dated 11/03/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ALKS #BMRN #INCY #XON #IONS #MDCO #OGXI #SGMO #ZIOP
MTSL Issue 837
MTSL Issue 837 (10/06/16) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #INCY #IONS #MDCO #NKTR #XON
MTSL Issue 835
MTSL Issue 835 (dated 9/8/16) of Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis & updates from these companies: #ANTH #BMRN #XON #MDCO #SGMO
MTSL Issue 833
MTSL Issue 833 (dated 8/11/16) of Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis & updates from these companies: #ACAD #ANTH #BMRN #FPRX #INCY #XON #IONS #MDCO #NKTR #NVAX #PCRX #SGMO #ZIOP
MTSL Issue 829
MTSL Issue 829 (dated 6/09/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #FPRX #INCY #IONS #XON #NVAX #MDCO #SGMO #ZIOP
MTSL Issue 828
MTSL Issue 828 (dated 5/26/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #
Anacor (ANAC) Buyout By Pfizer (PFE) (5-16-16)
BIOINVEST BREAKING NEWS â Special Update â ACAD â Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel â Acadiaâs Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drugâs overall risk/benefit for Parkinsonâs disease psychosis (PDP). Read more…
MTSL Issue 827
MTSL Issue 827 (dated 5/12/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ANTH #FPRX #INCY #IONS #XON #MDCO #NKTR #NVAX #PCRX #ZIOP
MTSL Issue 826
MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP
Intrexon Update (4-21-16)
BIOINVEST BREAKING NEWS â Special Update â ACAD â Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel â Acadiaâs Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drugâs overall risk/benefit for Parkinsonâs disease psychosis (PDP). Read more…
MTSL Issue 825
MTSL Issue 825 (dated 4/14/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #BMRN #IONS #XON #MDCO
Acadia Update (3-29-16)
BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…
MTSL Issue 824
MTSL Issue 824 (dated 3/31/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ALKS #INCY #XON #MDCO
MTSL Issue 823
MTSL Issue 823 (dated 3/17/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ANTH #FPRX #INCY #XON #OGXI #ZIOP
MTSL Issue 822
MTSL Issue 822 (dated 3/3/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ALKS #BMRN #XON #IONS #NKTR #NVAX #PCRX #SGMO #XON #ZIOP
MTSL Issue 821
MTSL Issue 821 (dated 2/18/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies:#INCY #XON #MDCO #NVAX #SGMO #ZIOP
MTSL Issue 820
MTSL Issue 820 (dated 2/4/16) of the Medical Technology #Stock Letter from Bioinvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ALKS #CBMG #INCY #XON #MDCO #NKTR #NVAX
Intrexon Update (1-7-16)
Intrexon (XON) – Two Health Care Deals Signed For Metabolic Diseases and RA â The first deal is with Janssen Pharmaceutica NV (JNJâs Euro Division) is to discover and develop ActoBiotics therapies directed against selected targets to treat Type 2 diabetes (T2D), obesity and/or metabolic disorders related to energy dysregulation. XONâs ActoBiotics platform represents an innovative oral delivery system for biological effectors ideally suited to tackle multiple aspects of T2D with the potential to improve efficacy in maintaining glycemic control in the long term. Read more…
MTSL Issue 818
Issue No. 818 (dated 1/7/16) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ACAD #ANTH #CBMG #FPRX #XON #PCRX
MTSL Issue 816
Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP
MTSL Issue 815
Issue No. 815 (dated 11/12/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #ACAD, #FPRX, #INCY, #ISIS, #MDCO, #NKTR, #NVAX, #OGXI, #XON
MTSL Issue 814
Issue No. 814 (dated 10/29/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS, #CBMG, #IMGN, #MDCO, #NVAX, #OGXI, #PCRX, #SGMO, #XON
Ziopharm Update (4-2-15)
ZIOP/XON Form Solid Partnerships With Merck KgaA & NCI CAR-T Superstar Rosenberg for Solid Tumors â ZIOPâs partner Intrexon (XON) has delivered two more exciting partnerships that ZIOP receives 50% of all assets and economics. The fact that the deals were both primarily announced by XON has caused a bit of confusion. For example, …